Article
Cell & Tissue Engineering
Eun Wha Choi, I. -Rang Lim, Ji Hong Park, Jiwoo Song, Bongkum Choi, Sungjoo Kim
Summary: Exosomes derived from disease-condition-serum-primed iMSCs showed potential in ameliorating cartilage damage in a RA model by enhancing TGF-beta 1 production, inducing Th2 and M2 polarization, and lowering proinflammatory cytokines levels. Patient-derived serum could be a valuable priming strategy for iMSC-derived exosome treatment of RA.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Rheumatology
Liam J. O'Neil, Christopher B. Oliveira, Xinghao Wang, Mario Navarrete, Ana Barrera-Vargas, Javier Merayo-Chalico, Rwan Aljahdali, Eduardo Aguirre-Aguilar, Philip Carlucci, Mariana J. Kaplan, Carmelo Carmona-Rivera
Summary: Neutrophil infiltration into the synovial joint is a hallmark of rheumatoid arthritis (RA). This study found that carbamylation, a posttranslational modification, is linked to increased bone erosion in RA. The researchers demonstrated that neutrophil extracellular traps (NETs) and their carbamylated protein cargo directly promote bone destruction by inducing osteoclast formation.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Kevin L. Winthrop, Peter Nash, Kunihiro Yamaoka, Eduardo Mysler, Nasser Khan, Heidi S. Camp, Yanna Song, Jessica L. Suboticki, Jeffrey R. Curtis
Summary: In patients with RA, treatment with Upadacitinib (UPA) was associated with higher incidence and event rates of herpes zoster (HZ) compared to treatment with methotrexate (MTX) monotherapy or adalimumab (ADA) + MTX. The risk of HZ was also higher with the 30 mg dose of UPA compared to the 15 mg dose. Patients from Asia and those with a history of HZ may have an increased risk of HZ while receiving UPA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Shigeru Iwata, Mingzeng Zhang, Maiko Hajime, Naoaki Ohkubo, Koshiro Sonomoto, Keiichi Torimoto, Yukihiro Kitanaga, Gulzhan Trimova, Yasuyuki Todoroki, Hiroko Miyata, Masanobu Ueno, Atsushi Nagayasu, Ryuichiro Kanda, Kazuhisa Nakano, Shingo Nakayamada, Kei Sakata, Yoshiya Tanaka
Summary: This study investigated the role of mTOR in B cells in rheumatoid arthritis, showing that mTOR activation in CXCR3(+) memory B cells is associated with disease activity and mediated through IL-6 production and RANKL expression. Additionally, treatment with TNF inhibitors had an impact on the association between CXCL10 and mTOR activated CXCR3(+) memory B cells.
Review
Health Care Sciences & Services
Mariangela Manfredi, Lieve Van Hoovels, Maurizio Benucci, Riccardo De Luca, Carmela Coccia, Pamela Bernardini, Edda Russo, Amedeo Amedei, Serena Guiducci, Valentina Grossi, Xavier Bossuyt, Carlo Perricone, Maria Infantino
Summary: uPAR is a membrane-bound glycoprotein, and its bioactive form, suPAR, is primarily expressed on the surface of immunologically active cells. Higher levels of suPAR have been associated with disease severity, relapse, and mortality in various inflammatory diseases. This review summarizes the current literature on the potential role of suPAR as a biomarker in autoimmune rheumatic and non-rheumatic diseases.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Rheumatology
Hilde Julie T. Lien, Tina T. Pedersen, Bente Jakobsen, Arnar Flatberg, Konika Chawla, Pal Saetrom, Mona H. Fenstad
Summary: The study compared cellular composition and peripheral blood gene expression in Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and healthy pregnancies. The results showed distinct RA, SLE, and pregnancy signatures that were not attributed to medication or disease activity. The study supports the need for close postpartum follow-up of patients with SLE and highlights the importance of cell-type adjustment in gene expression analysis.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Biochemical Research Methods
Zahra Payandeh, Abbas Pirpour Tazehkand, Ali Azargoonjahromi, Faezeh Almasi, Armina Alagheband Bahrami
Summary: Auto-immune diseases affect a significant portion of the population in wealthy countries, with Rheumatoid Arthritis being a common autoimmune disease. This condition can lead to synovial inflammation and joint injury, and exosomes have emerged as potential therapeutic vectors for treating such diseases.
BIOLOGICAL PROCEDURES ONLINE
(2021)
Article
Rheumatology
Achilleas Floudas, Nuno Neto, Carl Orr, Mary Canavan, Phil Gallagher, Conor Hurson, Michael G. Monaghan, Sunil Nagpar, Ronan H. Mullan, Douglas J. Veale, Ursula Fearon
Summary: This study investigates pathogenic and protective polyfunctional T-cell responses in patients with rheumatoid arthritis (RA), individuals at risk (IAR), and healthy controls (HC) synovial tissue biopsies, identifying a novel population of pathogenic polyfunctional T-cells enriched in RA joints prior to clinical inflammation. Results show increased plasticity of Tfh cells and CD4 T-cell polyfunctionality in RA patients, with enrichment of memory Treg cell responses. The switch from potentially protective to pathogenic T-cell polyfunctionality prior to clinical inflammation highlights a potential therapeutic intervention opportunity in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Nanoscience & Nanotechnology
Hanghang Fang, Yongjie Sha, Liang Yang, Jingjing Jiang, Lichen Yin, Jiaying Li, Bin Li, Bert Klumperman, Zhiyuan Zhong, Fenghua Meng
Summary: By nano-formulating hydroxychloroquine and designing it as a macrophage-targeted nanotherapeutic, it is possible to achieve highly effective treatment for rheumatoid arthritis. This therapeutic approach can induce repolarization of macrophages towards an anti-inflammatory phenotype, effectively reducing inflammation, and has shown significant therapeutic effects in mouse models.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Rheumatology
Eunji Ha, Sang-Cheol Bae, Kwangwoo Kim
Summary: A large trans-ancestral meta-analysis identified 11 new susceptibility loci for RA, explaining a significant portion of the heritability in East Asians and Europeans, and confirmed 71 known non-HLA susceptibility loci. The study also highlighted the importance of CD4(+) T-cell activation and potential non-immune organs in RA pathogenesis, providing insights into genetic etiology and variant-driven RA pathogenesis.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Anella Saviano, Adel Abo Manosour, Federica Raucci, Francesco Merlino, Noemi Marigliano, Anna Schettino, Mussarat Wahid, Jenefa Begum, Andrew Filer, Julia E. Manning, Gian Marco Casillo, Marialuisa Piccolo, Maria Grazia Ferraro, Simona Marzano, Pasquale Russomanno, Rosa Bellavita, Carlo Irace, Jussara Amato, Mohammed Alfaifi, Peter Rimmer, Tariq Iqbal, Stefano Pieretti, Valentina Vellecco, Francesco Caso, Luisa Costa, Roberto Giacomelli, Raffaele Scarpa, Giuseppe Cirino, Mariarosaria Bucci, Helen M. McGettrick, Paolo Grieco, Asif Jilani Iqbal, Francesco Maione
Summary: This study identified a novel IL-17A/F-derived peptide and generated a new anti-IL-17 antibody that can effectively reverse the pro-inflammatory actions of IL-17A/F. The antibody showed less off-target effects compared to the current gold-standard biologic. Preclinical and clinical evidence demonstrated the high efficacy and therapeutic potency of the antibody in patients with IMIDs.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Takashi Higuchi, Shomi Oka, Hiroshi Furukawa, Kota Shimada, Shinichiro Tsunoda, Satoshi Ito, Akira Okamoto, Masao Katayama, Koichiro Saisho, Satoshi Shinohara, Toshihiro Matsui, Kiyoshi Migita, Shouhei Nagaoka, Shigeto Tohma
Summary: This study is the first to show an association between the rs2609255 variant of the FAM13A gene and interstitial lung disease (ILD) in Japanese patients with rheumatoid arthritis (RA), suggesting its involvement in the pathogenesis of usual interstitial pneumonia (UIP). Further studies on the function of rs2609255 are needed.
Article
Immunology
Qiong Wang, Qinbin Ye, Xiaoyu Xi, Xiaoxue Cao, Xing Wang, Mengxiao Zhang, Yuan Xu, Tingting Deng, Xiaobing Deng, Guoqiang Zhang, Cheng Xiao
Summary: This study explored the association between RIPK1-dependent necroptosis and the pathogenesis of rheumatoid arthritis (RA), and identified a potential new treatment option. The plasma levels of RIPK1 and MLKL were found to be higher in RA patients and positively correlated with disease severity. Treatment with KW2449, a small molecule inhibitor targeting RIPK1, reduced joint inflammation and tissue damage in an animal model of RA. These findings suggest that RIPK1-dependent necroptosis could be a therapeutic target for RA.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Rheumatology
Pedro Santos-Moreno, Gabriel Burgos-Angulo, Maria Alejandra Martinez-Ceballos, Alejandro Pizano, Dario Echeverri, Paula K. Bautista-Nino, Anton J. M. Roks, Adriana Rojas-Villarraga
Summary: Traditional and non-traditional risk factors for cardiovascular disease have been established, with age and inflammation being important factors. Individuals with autoimmune diseases are more likely to experience accelerated vascular aging, leading to higher morbidity and mortality rates from cardiovascular disease. The beneficial impact of treatments for rheumatoid arthritis on cardiovascular health has opened new opportunities for pharmacotherapy.
Article
Biochemistry & Molecular Biology
Ju-Eun Hong, Chang-Gun Lee, Soonjae Hwang, Junyoung Kim, Minjeong Jo, Da-Hye Kang, Sang-Hyeon Yoo, Woo-Seung Kim, Yongheum Lee, Ki-Jong Rhee
Summary: This study found that pulsed electromagnetic field (PEMF) can alleviate inflammation in rheumatoid arthritis (RA), particularly at a frequency of 10 Hz. The treated mice had lower levels of joint inflammation and IL-1 beta. The results suggest that PEMF treatment can preserve joint morphology and delay the occurrence of RA.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Rheumatology
Mithu Maheswaranathan, Atul Kapila, Sarah Cater, Teresa Kathleen Tarrant
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2022)
Editorial Material
Allergy
Akrithi Udupa, David Leverenz, Stephen J. Balevic, Rebecca E. Sadun, Teresa K. Tarrant, Jennifer L. Rogers
Summary: Despite the ongoing debate about the primary mode of action of hydroxychloroquine, the literature does not support its use in treating or preventing SARS-CoV-2 virus infection. Nevertheless, hydroxychloroquine continues to be widely used in the treatment of rheumatic diseases, and its therapeutic versatility has led to its recent repurposing for other conditions, including as an investigative treatment against the novel coronavirus.
CURRENT ALLERGY AND ASTHMA REPORTS
(2021)
Review
Allergy
Philip Chu, Maria C. Cuellar, Sonali J. Bracken, Teresa K. Tarrant
Summary: Ochronosis and alkaptonuria are manifestations of the same rare autosomal recessive disorder caused by a deficiency of homogentisate 1,2-dioxygenase, leading to the accumulation of homogentisic acid. While initially presenting with homogentisic aciduria and pigmentation, the condition progresses to ochronotic arthropathy in later years.
CURRENT ALLERGY AND ASTHMA REPORTS
(2021)
Review
Allergy
Emily M. Rabjohns, Katlyn Hurst, Arin Ghosh, Maria C. Cuellar, Rishi R. Rampersad, Teresa K. Tarrant
Summary: Understanding the pathologic mechanisms in the Pagetic osteoclast may lead to the identification of future treatment targets for other inflammatory and autoimmune diseases characterized by abnormal bone erosion and/or osteoclast activation.
CURRENT ALLERGY AND ASTHMA REPORTS
(2021)
Article
Multidisciplinary Sciences
Korbinian Kienle, Katharina M. Glaser, Sarah Eickhoff, Michael Mihlan, Konrad Knoepper, Eduardo Reategui, Maximilian W. Epple, Matthias Gunzer, Ralf Baumeister, Teresa K. Tarrant, Ronald N. Germain, Daniel Irimia, Wolfgang Kastenmueller, Tim Laemmermann
Summary: The study found that neutrophils have evolved an intrinsic mechanism to limit self-aggregation during inflammation, with GPCR desensitization acting as a negative feedback control to stop migration when high concentrations of attractants are detected. However, interfering with this process may hinder bacterial clearance, as bacteria proliferation within neutrophil clusters becomes impeded. This highlights the delicate balance of neutrophil chemotaxis and arrest in combating bacterial escape.
Article
Rheumatology
Elizabeth J. Malcolm, Zachary Brandon, Lauren E. Wilson, John Paul Shoup, Heather A. King, Allison Lewinski, Melissa A. Greiner, Shauna Malone, Julie Miller, Robert T. Keenan, Teresa K. Tarrant, Donna Phinney, Alex Cho, Hayden B. Bosworth, Kevin Shah
Summary: This study evaluated the implementation of eConsults in rheumatology and its impact on wait times for in-person visits. The results showed that eConsults were associated with reduced wait times for rheumatology appointments and supported primary care providers in triage and workup for a substantial portion of patients.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2022)
Article
Allergy
Iris M. Otani, Heather K. Lehman, Artemio M. Jongco, Lulu R. Tsao, Antoine E. Azar, Teresa K. Tarrant, Elissa Engel, Jolan E. Walter, Tho Q. Truong, David A. Khan, Mark Ballow, Charlotte Cunningham-Rundles, Huifang Lu, Mildred Kwan, Sara Barmettler
Summary: Secondary hypogammaglobulinemia is characterized by reduced immunoglobulin levels due to decreased antibody production or increased loss. It is important to determine whether the hypogammaglobulinemia is secondary or primary for evaluation and management. Patients with a history of immunosuppressive medications or conditions associated with SHG require thorough investigation to determine the underlying causes and devise effective treatment plans. When iatrogenic causes cannot be removed or underlying conditions cannot be reversed, monitoring for clinical infections, supportive antimicrobials, and immunoglobulin replacement therapy may be considered.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Jaime M. Brozowski, Roman G. Timoshchenko, D. Stephen Serafin, Brittney Allyn, Jessica Koontz, Emily M. Rabjohns, Rishi R. Rampersad, Yinshi Ren, Amanda M. Eudy, Taylor F. Harris, David Abraham, Daniel Mattox, Clinton T. Rubin, Matthew J. Hilton, Janet Rubin, Nancy L. Allbritton, Matthew J. Billard, Teresa K. Tarrant
Summary: Our study reveals that G protein receptor kinase 3 (GRK3) regulates the function of bone marrow mesenchymal stem cells by modulating sphingosine-1-phosphate receptor signaling. Deficiency of GRK3 leads to hypercellular bone marrow and leukocytosis, as well as enhanced osteogenic differentiation of mesenchymal stem cells. These findings highlight the important role of GRK3 in the bone marrow niche.
STEM CELL RESEARCH & THERAPY
(2022)
Meeting Abstract
Biochemistry & Molecular Biology
Sara C. Campbell, Marko Oydanich, Jie Zhang, Candace R. Longoria, Dorothy E. Vatner, David P. Siderovski, Stephen F. Vatner
Review
Allergy
Megan E. Milne, Jack Kimball, Teresa K. Tarrant, Rami N. Al-Rohil, David L. Leverenz
Summary: This article reviews the role of IL-4, IL-5, and IL-13 in eosinophilic granulomatosis with polyangiitis (eGPA) and discusses the potential clinical consequences of inhibiting these cytokines.
CURRENT ALLERGY AND ASTHMA REPORTS
(2022)
Article
Immunology
Katharina M. Glaser, Teresa K. Tarrant, Tim Laemmermann
Summary: G-protein coupled receptor kinases (GRKs) participate in the regulation of chemokine receptors, but they also have other functions beyond GPCR desensitization in primary immune cells. The interplay between different GRK family members and their effects on different immune cell types and GPCRs are complex and unpredictable. This study demonstrates the importance of studying GRK functions in primary immune cells to understand their specific roles.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Emily M. Rabjohns, Rishi R. Rampersad, Arin Ghosh, Katlyn Hurst, Amanda M. Eudy, Jaime M. Brozowski, Hyun Ho Lee, Yinshi Ren, Anthony Mirando, Justin Gladman, Jessica L. Bowser, Kathryn Berg, Sachin Wani, Stuart H. Ralston, Matthew J. Hilton, Teresa K. Tarrant
Summary: Paget's Disease of Bone (PDB) is a metabolic bone disease characterized by dysregulated osteoclast function. Our study found that GRK3, a negative regulator of GPCR signaling, is relevant to the regulation of osteoclast differentiation and may be involved in the pathogenesis of PDB and other metabolic bone diseases associated with osteoclast activation.
Article
Pharmacology & Pharmacy
Emilia M. Zywot, Natalia Orlova, Song Ding, Rishi R. Rampersad, Emily M. Rabjohns, Victoria A. Wickenheisser, Qunzhao Wang, Joshua G. Welfare, Lauren Haar, Amanda M. Eudy, Teresa K. Tarrant, David S. Lawrence
Summary: Arthritis is a leading cause of disability in adults, with the location and intensity of pain being subjective and challenging to manage. Patient-directed use of anti-inflammatories is an essential therapeutic strategy. A light-responsive red blood cell-conveyed dexamethasone construct allows targeted drug delivery to inflamed sites, significantly outperforming traditional drug delivery methods in suppressing inflammation.
ADVANCED THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Teresa K. Tarrant, Susan J. Kelly, Michael S. Hershfield
Summary: Humans have two adenosine deaminase isozymes, ADA1 and ADA2, which have different affinities and localizations. ADA1 deficiency affects immune and hematological function, while the function of ADA2 is still uncertain. Various proposed mechanisms related to ADA2 enzymatic activity have not yet been fully supported by evidence.
EXPERT OPINION ON ORPHAN DRUGS
(2021)
Meeting Abstract
Cardiac & Cardiovascular Systems
Sara C. Campbell, Marko Oydanich, Jie Zhang, Candace R. Longoria, Olufunmilola Ibironke, Dorothy E. Vatner, David P. Siderovski, Stephen F. Vatner